$7.01
3.04%
Nasdaq, Sep 05, 10:16 pm CET
ISIN
US89532M1018
Symbol
TRVI

Trevi Therapeutics, Inc. Stock price

$7.01
-0.40 5.40% 1M
+2.62 59.68% 6M
+2.89 70.15% YTD
+3.91 126.13% 1Y
+3.80 118.38% 3Y
+3.40 94.18% 5Y
-0.88 11.15% 10Y
-0.88 11.15% 20Y
Nasdaq, Closing price Fri, Sep 05 2025
-0.22 3.04%
ISIN
US89532M1018
Symbol
TRVI
Industry

Key metrics

Basic
Market capitalization
$853.7m
Enterprise Value
$649.8m
Net debt
positive
Cash
$203.9m
Shares outstanding
121.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.3
Financial Health
Equity Ratio
89.9%
Return on Equity
-48.1%
ROCE
-25.9%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-51.4m | $-62.8m
EBIT
$-51.5m | $-56.6m
Net Income
$-47.3m | $-48.7m
Free Cash Flow
$-42.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-19.9% | -22.3%
EBIT
-19.9% | -9.9%
Net Income
-22.8% | -1.6%
Free Cash Flow
-31.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
9.6%
Employees
26
Rev per Employee
$0.0
Show more

Is Trevi Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Trevi Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Trevi Therapeutics, Inc. forecast:

16x Buy
94%
1x Hold
6%

Analyst Opinions

17 Analysts have issued a Trevi Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Trevi Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
20% 20%
-
- Research and Development Expense 38 38
19% 19%
-
-51 -51
20% 20%
-
- Depreciation and Amortization 0.15 0.15
7% 7%
-
EBIT (Operating Income) EBIT -52 -52
20% 20%
-
Net Profit -47 -47
23% 23%
-

In millions USD.

Don't miss a Thing! We will send you all news about Trevi Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Trevi Therapeutics, Inc. Stock News

Neutral
PRNewsWire
11 days ago
NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)  for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that...
Neutral
Seeking Alpha
about one month ago
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commercial Officer James V. Cassella - Chief Development Officer Jennifer L.
Neutral
PRNewsWire
about one month ago
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway into 2029 Management to host a conference call and webcast today at 4:30 p.m. ET    NEW HAVEN, Conn.
More Trevi Therapeutics, Inc. News

Company Profile

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.

Head office United States
CEO Jennifer Good
Employees 26
Founded 2011
Website www.trevitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today